Click here to visit NeuVax.com

Study Description

“PRESENT”

Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment

Endpoint

Disease free survival at 3 years

Key Eligibility Criteria

• Node Positive (NP)
• HER2 1+ or 2+
• HLA A2 or HLA A3 Positive
• No evidence of disease (NED) following Standard of Care

Intradermal injection once per month for 6 months (6 total), followed by boosters shots once every 6 months (5 total) for a total of 11 shots over 3 years.